INDIA – Global pharmaceutical company, Boehringer Ingelheim has received approval from the Central Drugs Standard Control Organization (CDSCO) to market its innovative cardiac drug Jardiance (empagliflozin) in India. Following Jardiance’s…
Read MoreTag: Boehringer Ingelheim
Boehringer, VantAI collaborate to identify novel protein degraders
GERMANY –Boehringer Ingelheim and biotech startup VantAI have entered into an early discovery research collaboration to identify new protein degraders with enhanced properties against traditionally “undruggable” disease targets, the companies…
Read MoreBoehringer backs AI-powered drug discovery startup ArrePath
USA – ArrePath, a drug discovery startup, announced a US$20 million seed funding round led by the Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures. Viva BioInnovator, Arimed Capital,…
Read MoreBoehringer Ingelheim and Lifebit partner on data, analytics for drug discovery
GERMANY – Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and Lifebit Biotech, Ltd, a precision medicine software company, have announced a partnership in which Lifebit will assist Boehringer Ingelheim in…
Read MoreLilly & Boehringer’s Jardiance wins FDA nod for treating wider range of patients with heart failure
USA – The FDA announced that Jardiance (empagliflozin) by Eli Lilly and Boehringer Ingelheim has been approved to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure…
Read MoreLilly, Evotec partner to develop drugs for metabolic diseases
USA – Eli Lilly and Company has announced a drug discovery collaboration with Evotec in the field of metabolic diseases, with a focus on kidney diseases and diabetes. The three-year…
Read MoreBlueprint Medicines expands oncology portfolio by acquiring Lengo Therapeutics for US$465 million
USA – Blueprint Medicines, a US-based biotech that specializes in targeted cancer drugs, is set to pay US$250 million in cash and another US$215 million in potential milestone payments to…
Read MoreAstraZeneca unveils new discovery center (DISC) in Cambridge, UK
UNITED KINGDOM – AstraZeneca, a global, science-led biopharmaceutical company has opened a billion-pound research center near the University of Cambridge hoping to build on the work in developing one of…
Read MoreBoehringer Ingelheim’s Jardiance scores marketing nod in India for additional indication
INDIA – Indian drug regulator, the Drugs Controller General of India (DCGI) has given Boehringer Ingelheim permission to market Jardiance (empagliflozin) in India for an additional indication to reduce heart…
Read MoreClick Therapeutic secures US$52 million in Series B funding to expand prescription portfolio
USA – Click Therapeutic, a prescription digital therapeutic company, has bagged US$52 million Series B funding round led by Health Catalyst Capital, Revelation Partners, Sanofi, K2 HealthVentures, Hima Ventures, and…
Read More